NO20055880L - Memantin orale doseringsformer - Google Patents

Memantin orale doseringsformer

Info

Publication number
NO20055880L
NO20055880L NO20055880A NO20055880A NO20055880L NO 20055880 L NO20055880 L NO 20055880L NO 20055880 A NO20055880 A NO 20055880A NO 20055880 A NO20055880 A NO 20055880A NO 20055880 L NO20055880 L NO 20055880L
Authority
NO
Norway
Prior art keywords
memantine
dosage form
dosage forms
oral dosage
memantine oral
Prior art date
Application number
NO20055880A
Other languages
English (en)
Inventor
Bruce A Firestone
John J Vander Zanden
Janet K Cheetham
Richard Kurjan
Teresa H Kuan
Ching-Ming Chang
J Abraham M Espiritu
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of NO20055880L publication Critical patent/NO20055880L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Det beskrives oral doseringsform som inneholder mellom 1 mg og 100 mg av memantin, hvor doseringsformen ikke inneholder 10 mg av memantin eller 20 mg av memantin, og hvor doseringsformen ikke blir tillaget av pasienten eller en person som administrerer drogen til pasienten som oppdeler doseringsformen som inneholder en større dose av memantin. Andre aspekter vedrører farmasøytiske produkter som omfatter de nevnte doseringsformer og fremgangsmåter for a administrere memantin og behandle sykdom med nevnte doseringsform.
NO20055880A 2003-06-16 2005-12-12 Memantin orale doseringsformer NO20055880L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47897903P 2003-06-16 2003-06-16
PCT/US2004/018506 WO2004112768A1 (en) 2003-06-16 2004-06-10 Memantine oral dosage forms

Publications (1)

Publication Number Publication Date
NO20055880L true NO20055880L (no) 2005-12-28

Family

ID=33539133

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20055880A NO20055880L (no) 2003-06-16 2005-12-12 Memantin orale doseringsformer

Country Status (16)

Country Link
US (2) US20040254251A1 (no)
EP (1) EP1631273A1 (no)
JP (1) JP2006527774A (no)
KR (1) KR20060033727A (no)
CN (1) CN1805737A (no)
AU (1) AU2004249151A1 (no)
BR (1) BRPI0411451A (no)
CA (1) CA2529535A1 (no)
IL (1) IL172233A0 (no)
MX (1) MXPA05012810A (no)
NO (1) NO20055880L (no)
PL (1) PL378902A1 (no)
RU (1) RU2006101225A (no)
TW (1) TW200524639A (no)
WO (1) WO2004112768A1 (no)
ZA (1) ZA200509379B (no)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7086532B2 (en) * 2003-07-16 2006-08-08 Allergan, Inc. Titration/compliance pack with increasing doses
FR2855344A1 (fr) * 2003-05-22 2004-11-26 France Telecom Systeme de gestion de contexte pour un reseau comportant un ensemble heterogene de terminaux
US20060002999A1 (en) * 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
EP2397122B1 (en) * 2004-06-17 2014-05-14 Merz Pharma GmbH & Co. KGaA Formulations of neramexane dosage forms
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
DE05852057T1 (de) * 2004-11-23 2007-11-29 Neuromolecular Pharmaceuticals Inc., Emeryville Zusammensetzung aus einer beschichtung oder matrix mit verzögerter freisetzung und einem nmda-rezeptorantagonisten sowie verfahren zur verabreichung eines solchen nmda-rezeptorantagonisten an ein subjekt
US20060159753A1 (en) * 2004-12-27 2006-07-20 Eisai Co. Ltd. Matrix type sustained-release preparation containing basic drug or salt thereof
JP2008525313A (ja) 2004-12-27 2008-07-17 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗痴呆薬の安定化方法
US20060160852A1 (en) * 2004-12-27 2006-07-20 Eisai Co. Ltd. Composition containing anti-dementia drug
DE602006016934D1 (de) 2005-04-06 2010-10-28 Adamas Pharmaceuticals Inc Verfahren und zusammensetzungen zur behandlung von zns-erkrankungen
NZ562120A (en) * 2005-04-28 2010-07-30 Eisai R&D Man Co Ltd Composition comprising donepezil and memantine as antidementia agents
DE602007003697D1 (de) * 2006-02-10 2010-01-21 Janssen Pharmaceutica Nv Ffner
US20090176736A1 (en) * 2006-04-20 2009-07-09 Katsumi Dohura Pharmaceutical composition for conformational diseases
JP2009542647A (ja) * 2006-07-05 2009-12-03 テバ ファーマシューティカル インダストリーズ リミティド メマンチン医薬組成物
EP1908748A1 (en) * 2006-10-05 2008-04-09 Krka Process for the preparation of memantine and its hydrochloric acid salt form
BRPI0718437A2 (pt) * 2006-10-27 2013-11-19 Medivation Neurology Inc Métodos e terapias de combinação para tratar a doença de alzheimer usando, entre outros, dimebon e dolepezil
US20080182908A1 (en) * 2007-01-25 2008-07-31 Vinita Umashankar Vyas Pharmaceutical compositions comprising memantine
WO2009004440A2 (en) * 2007-06-29 2009-01-08 Orchid Chemicals & Pharmaceuticals Limited Quick dissolve compositions of memantine hydrochloride
WO2009084017A2 (en) 2007-10-10 2009-07-09 Rubicon Research Private Limited Taste-masked orally disintegrating tablets of memantine hydrochloride
WO2009091932A2 (en) * 2008-01-18 2009-07-23 Adamas Pharmaceuticals, Inc. Treatment of mild dementia of the alzheimer's disease type
US20090247644A1 (en) * 2008-03-28 2009-10-01 Forest Laboratories Holdings Limited Memantine formulations
AU2010325960C1 (en) 2009-12-02 2015-08-06 Adamas Pharma, Llc Amantadine compositions and methods of use
KR101943686B1 (ko) * 2012-04-24 2019-01-29 다이이찌 산쿄 가부시키가이샤 구강내 붕괴정 및 그 제조 방법
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
KR20190076711A (ko) 2017-12-22 2019-07-02 한미약품 주식회사 메만틴을 포함하는 속방성 및 서방성을 동시에 가지는 경질캡슐 제제 및 그 제조방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2856393C2 (de) * 1978-12-27 1983-04-28 Merz + Co GmbH & Co, 6000 Frankfurt Arzneimittel zur Behandlung von Morbus Parkinson
AUPN605795A0 (en) * 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
US6057373A (en) * 1997-05-22 2000-05-02 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders using NMDA receptor antagonists
US6849271B2 (en) * 2001-04-27 2005-02-01 Verion, Inc. Microcapsule matrix microspheres, absorption-enhancing pharmaceutical compositions and methods

Also Published As

Publication number Publication date
PL378902A1 (pl) 2006-05-29
CN1805737A (zh) 2006-07-19
AU2004249151A1 (en) 2004-12-29
JP2006527774A (ja) 2006-12-07
RU2006101225A (ru) 2006-06-10
BRPI0411451A (pt) 2006-07-18
ZA200509379B (en) 2006-11-29
IL172233A0 (en) 2006-04-10
CA2529535A1 (en) 2004-12-29
KR20060033727A (ko) 2006-04-19
MXPA05012810A (es) 2006-02-13
EP1631273A1 (en) 2006-03-08
WO2004112768A1 (en) 2004-12-29
US20040254251A1 (en) 2004-12-16
US20060251717A1 (en) 2006-11-09
TW200524639A (en) 2005-08-01

Similar Documents

Publication Publication Date Title
NO20055880L (no) Memantin orale doseringsformer
RU2008119454A (ru) Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
RU2010105122A (ru) Композиции для ухода за полостью рта, продукты и способы применения
AR050418A1 (es) Dosificacion fija de anticuerpos her
BRPI0513200A (pt) uso de um anticorpo anti-igf-1r na preparação de um medicamento para tratamento combinado para malignidades não-hematológicas
ES2153338T1 (es) Dosificacion mejorada de dosis multiples de medicamentos.
RU2007132181A (ru) ПРОТИВОРАКОВОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ α,α,α-ТРИФТОРТИМИДИН И ИНГИБИТОР ТИМИДИНФОСФОРИЛАЗЫ
TWI455723B (zh) 納曲酮及安非他酮於治療超重或肥胖病患之用途
BR9909672A (pt) uso de um composto medicinal ativo no preparo de um medicamento para o tratamento de hipertensão
CU23468B7 (es) Forma de dosificación de pramipexol en una dosis única diaria
DE69920689D1 (de) Vorrichtungen um eine verlängerte medikamententherapie zu erreichen
RU2008122358A (ru) Лекарственные формы, содержащие ag013736
ATE298324T1 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
ES2524369T3 (es) Unidad de dosificación que incluye un análogo de prostaglandina para el tratamiento del estreñimiento
NO20080244L (no) Doseringsstyring for prasugrel
KR970025615A (ko) 암 전이 억제제
KR970061244A (ko) 치매 치료용 약학 조성물
ES2175663T3 (es) Composiciones farmaceuticas solidas que contienen miltefosina para administracion oral en el tratamiento de la leshmaniasis.
AR026254A1 (es) El uso de una preparacion de liberacion controlada para la preparacion de un medicamento para aumentar la dosis o la exposicion sistemica de un farmaco queinhibe la fosfodiesterasa 4
BR0115390A (pt) Formulações para liberação controlada de metformina, liberação controlada da forma farmacêutica oral, método de diminuição dos nìveis de glicose sanguìnea, uso da forma farmacêutica
BR0009380A (pt) Tratamento de câncer melhorado comtemozolomida
PE20040706A1 (es) Derivado especifico de amina ciclica y sus sales farmaceuticamente aceptables involucrados en la prevencion de la insuficiencia cardiaca
SE0102887D0 (sv) New formulation
KR960028907A (ko) 암환자를 치료하기 위한 세트랄린의 용도

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application